DD-01 is under clinical development by D&D Pharmatech and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DD-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DD-01 is under development for the treatment of severe obesity, type 2 diabetes and non-alcoholic steatohepatitis (NASH). It is a long-acting dual agonist of GLP-1 and glucagon receptors, acts by targeting glucagon like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR). It is administered through subcutaneous route.
For a complete picture of DD-01’s drug-specific PTSR and LoA scores, buy the report here.